Therefore, in this study, we hypothesize that melanoma cells resistant to RTKi/MAPKi undergo a metabolic switch toward glutaminolysis, and that this dependency can be therapeutically targeted using the glutaminase inhibitor CB-839 to overcome resistance and restore antitumor efficacy. This evidence concerns the gene GLS and melanoma.